PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>Tirzepatide>>dosing-education
Approved medicine

Tirzepatide Dosing Education: Structure, Not Schedules

How tirzepatide dosing is structured and why — educational only. Personal dosing decisions belong with prescribers and the approved label.

The escalation logic

Doses increase at four-week intervals toward maintenance strengths; the slow ramp exists to manage GI tolerability, and skipping escalation steps increases discontinuation risk.

Approved maintenance strengths

Mounjaro (T2D): up to 15 mg weekly. Zepbound (obesity): up to 15 mg weekly, with lower strengths used for maintenance after response. Single-dose pens are titration-staged.

Missed-dose handling

The label specifies the window for a late dose and — importantly — that missed doses are not doubled.

Why this page stops short

Schedules circulating online (including for compounded copies) describe products without verified identity or strength. The trial evidence on this site describes the approved medicine.

Educational content only — not medical advice. Dosing and treatment decisions belong with the approved label and a prescriber.

References

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. [source]
  2. ClinicalTrials.gov — registered tirzepatide studies. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement